Napo Pharmaceuticals Revenue and Competitors

Location

$12.1M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Napo Pharmaceuticals's estimated annual revenue is currently $1.6M per year.(i)
  • Napo Pharmaceuticals's estimated revenue per employee is $100,500
  • Napo Pharmaceuticals's total funding is $12.1M.

Employee Data

  • Napo Pharmaceuticals has 16 Employees.(i)
  • Napo Pharmaceuticals grew their employee count by -6% last year.

Napo Pharmaceuticals's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
National Business DirectorReveal Email/Phone
3
Specialty Territory ManagerReveal Email/Phone
4
Specialty Territory Business ManagerReveal Email/Phone
5
Specialty Territory ManagerReveal Email/Phone
6
Senior Product Marketing ManagerReveal Email/Phone
7
HIV Specialty Territory ManagerReveal Email/Phone
8
Medical AffairsReveal Email/Phone
9
Territory Sales RepresentativeReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$84.8M42224%N/AN/A
#2
$0.4M20%N/AN/A
#3
$32M1593%N/AN/A
#4
$35M1213%$62.5MN/A
#5
$30.2M15018%N/AN/A
#6
$135.3M6730%N/AN/A
#7
$110.3M549N/AN/AN/A
#8
$60.1M299-4%N/AN/A
#9
$554.8M17252%N/AN/A
#10
$10.5M524%N/AN/A
Add Company

What Is Napo Pharmaceuticals?

Napo Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company based in South San Francisco, California. Founded in November 2001, Napo is developing a late-stage drug candidate, crofelemer, for gastrointestinal indications including chronic diarrhea in persons living with HIV/AIDS. Additionally, Napo has entered into a licensing agreement for the worldwide development and commercialization of crofelemer for Irritable Bowel Syndrome. Napo is also working with private/public partners to jointly develop crofelemer for pediatric indications in the developing world while maintaining commercial rights in the developed world.

keywords:N/A

$12.1M

Total Funding

16

Number of Employees

$1.6M

Revenue (est)

-6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Napo Pharmaceuticals News

2022-04-13 - Jaguar Health Announces Replenishment of New Employee ...

Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human...

2022-03-30 - Jaguar Health Announces Appointment of Pravin Chaturvedi, Ph.D ...

Chaturvedi served as Chair of the company's SAB and Acting CSO of Jaguar and Napo Pharmaceuticals (Napo), Jaguar's wholly owned subsidiary. "We...

2022-03-22 - Jaguar Health Enters Exclusive Crofelemer Distribution and License ...

Jaguar Animal Health is a tradename of Jaguar Health. Jaguar Health's wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing...

2017-01-03 - Napo Pharmaceuticals Raises $2 Million from Kingdon Capital Management

SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc., announced today that it has obtained $2 million in secured convertible debt financing from New York-based Kingdon Capital Management, LLC. Proceeds from the financing will primarily be used by Napo for the commercialization of Mytesi™. ...

2011-12-14 - Salix files NDA for diarrhea drug despite dispute with partner Napo

Salix licensed crofelemer in 2008 from San Francisco, California drug developer Napo Pharmaceuticals, an agreement that paid Napo $4.5 million and called for Salix to be responsible for development of the compound. Crofelemer had been granted fast-track status by the U.S. Food and Drug Administr ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.4M16-27%N/A
#2
$0.5M16-70%$48.1M
#3
$0.5M16-16%$0.8M
#4
$1.4M16N/AN/A
#5
$0.6M167%$7.5M